Frequently Asked Questions about Amicus Therapeutics, Inc. (FOLD)

Name: Amicus Therapeutics, Inc. (FOLD) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Amicus Therapeutics, Inc. (FOLD) do?

Accepted Answer

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and a...

Question 2

Is Amicus Therapeutics, Inc. (FOLD) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of FOLD reveals an Altman Z-Score of 1.33 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.63B most recent), help investors decide if FOLD fits their risk profile.

Question 3

What is the current P/E ratio for FOLD?

Accepted Answer

As of the latest trading session, Amicus Therapeutics, Inc. (FOLD) has a trailing P/E ratio of -164.80.

Question 4

Who is the CEO of Amicus Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Amicus Therapeutics, Inc. is Bradley L. Campbell.

Question 5

What was FOLD's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Amicus Therapeutics, Inc. reported annual revenues of $0.63B (2025), $0.53B (2024), $0.40B (2023), $0.33B (2022), $0.31B (2021) respectively.

Question 6

Does FOLD pay a dividend?

Accepted Answer

Amicus Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does FOLD have?

Accepted Answer

In its latest reporting period, Amicus Therapeutics, Inc. generated $0.03B in Free Cash Flow against a total debt load of $0.48B.

Question 8

What is the Price-to-Book (P/B) ratio of Amicus Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Amicus Therapeutics, Inc. (FOLD) is currently 16.29.

Question 9

What is the Price-to-Sales (P/S) ratio of FOLD?

Accepted Answer

Based on trailing twelve-month data, Amicus Therapeutics, Inc. (FOLD) trades at a Price-to-Sales (P/S) ratio of 7.16.

Question 10

What is Amicus Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Amicus Therapeutics, Inc. (FOLD) has a Return on Equity (ROE) of -12.02%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	634.2M	553.8M	34.5M	-27.1M	-0.09
2024-12	528.3M	475.4M	24.9M	-56.1M	-0.18
2023-12	399.4M	362M	-77.2M	-151.6M	-0.51
2022-12	329.2M	290.6M	-212.1M	-236.6M	-0.82
2021-12	305.5M	271M	-206.4M	-250.5M	-0.92

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	634.2M	553.8M	34.5M	-27.1M	-0.09
2024-12	528.3M	475.4M	24.9M	-56.1M	-0.18
2023-12	399.4M	362M	-77.2M	-151.6M	-0.51
2022-12	329.2M	290.6M	-212.1M	-236.6M	-0.82
2021-12	305.5M	271M	-206.4M	-250.5M	-0.92